Synmosa Biopharma Corporation (TPEX:4114)

Market Cap	14.25B
Revenue (ttm)	5.38B
Net Income (ttm)	718.07M
Shares Out	420.25M
EPS (ttm)	1.71
PE Ratio	19.84
Forward PE	15.20
Dividend	0.55 (1.64%)
Ex-Dividend Date	Aug 9, 2024

Volume	432,631
Average Volume	1,446,830
Open	34.00
Previous Close	33.90
Day's Range	33.70 - 34.05
52-Week Range	32.25 - 38.35
Beta	0.29
RSI	44.49
Earnings Date	Mar 28, 2025

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, hormones, and other forms. In addition, it offers contract manufacturing serv...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1980
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4114

Financial Performance

In 2023, Synmosa Biopharma's revenue was 5.14 billion, an increase of 17.19% compared to the previous year's 4.39 billion. Earnings were 594.83 million, a decrease of -25.56%.